Markus Puhlmann - 11 Nov 2026 Form 4 Insider Report for Perspective Therapeutics, Inc. (CATX)

Reporting relationship: Chief Medical Officer
Issuer ticker: CATX
Reported as of: 11 Nov 2026
Net transaction value: +$34,544
SEC form: 4
Accepted by SEC: 13 Nov 2026, 08:30:04 UTC
Prior SEC filing: 04 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Markus Puhlmann by Chris Nenno, as Attorney-in-Fact

Filing notes and source

Key filing fact

Markus Puhlmann filed Form 4 for Perspective Therapeutics, Inc. (CATX) on 13 Nov 2026.

Key facts

This page summarizes Markus Puhlmann's Form 4 filing for Perspective Therapeutics, Inc. (CATX).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 13 Nov 2026, 08:30.

Change

Previous filing in this sequence was filed on 04 Mar 2026.
Current net transaction value: +$34,544.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001965071 Primary reporting owner

Puhlmann Markus

Relationship: Chief Medical Officer
Address: C/O PERSPECTIVE THERAPEUTICS, INC., 2401 ELLIOTT AVENUE, SUITE 320, SEATTLE
Signature: /s/ Markus Puhlmann by Chris Nenno, as Attorney-in-Fact
Signature date: 13 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CATX transaction

Common Stock

Purchase

Transaction value: $4,980
Shares: +6,000
Change %: +4.4%
Price: $0.8300
Shares after: 143,542
Date: 11 Nov 2026
Ownership: Direct

CATX transaction

Common Stock

Purchase

Transaction value: $29,564
Shares: +35,000
Change %: +24%
Price: $0.8447
Shares after: 178,542
Date: 12 Nov 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8408 to $0.8450, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the transactions described in this footnote.